
Eli Lilly shares jump 7%, biggest gain since February, driven by strong oncology and neuroscience prospects.
Eli Lilly's stock rose 7% in a single day, marking its largest gain since early February when it surged 10% after releasing 2025 results. The rise reflects broader gains in the healthcare sector but is notably driven by the company's advancements in ...


